Prelude Therapeutics Incorporated
PRLD
$4.66
$0.020.43%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
5/13/2026
-
Simply Wall St
5/12/2026
-
Globe Newswire
5/8/2026
-
Zacks Investment Research
5/8/2026
-
Zacks Investment Research
5/4/2026
-
The Cerbat Gem
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Given Consensus Recommendation of "Hold" by Analysts
5/4/2026
-
MarketBeat
5/4/2026
-
MarketBeat
5/2/2026
-
TipRanks Financial Blog
5/2/2026
-
TipRanks Financial Blog
5/1/2026
-
Insider Monkey
5/1/2026
-
Tickeron - Stocks
4/30/2026
-
Insider Monkey
4/30/2026
-
MarketBeat
4/29/2026
-
Tickeron - Stocks
4/28/2026
-
MarketBeat
4/27/2026
-
MarketBeat
4/25/2026
-
Tickeron - Technical Analysis
4/24/2026
-
Holdings Channel
4/24/2026
-
Tickeron - Stocks
4/24/2026
-
MarketBeat
4/23/2026
-
MarketBeat
4/23/2026
-
MarketBeat
4/23/2026
-
Tickeron - Technical Analysis
4/23/2026
-
Tickeron - Technical Analysis
4/22/2026
-
Tickeron - Stocks
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Tuesday, March 10, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 4 and 8 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
302 467 1280
Address
175 Innovation Boulevard
Wilmington, DE 19805
Wilmington, DE 19805
Country
Year Founded
Business Description
Sector
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is...
more